Reuters logo
4 months ago
BRIEF-Enzyvant receives FDA breakthrough therapy designation for investigational therapy rvt-802
April 17, 2017 / 8:51 PM / 4 months ago

BRIEF-Enzyvant receives FDA breakthrough therapy designation for investigational therapy rvt-802

April 17 (Reuters) -

* Enzyvant receives FDA breakthrough therapy designation and regenerative medicine advanced therapy designation for investigational therapy rvt-802

* Enzyvant says receives U.S FDA breakthrough therapy designation and regenerative medicine advanced therapy designation for its rvt-802

* Enzyvant says it anticipates potential bla filing in first half of 2018 Source text for Eikon:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below